Prevention of hepatocarcinogenesis with phosphatidylcholine and menaquinone-4: In vitro and in vivo experiments>

Journal of Hepatology

Volumn 47, Issue 1, 2007, Pages 83-92

  Sakakima, Yoshikazu ^a   Hayakawa, Akemi ^b   Nagasaka, Tetsuro ^a   Nakao, Akimasa ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

Apoptosis; Hepatocellular carcinoma; Menaquinone 4; Phosphatidylcholine

Indexed keywords

DIETHYLNITROSAMINE; GLUTATHIONE TRANSFERASE; MENATETRENONE; PHENOBARBITAL; PHOSPHATIDYLCHOLINE;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG POTENTIATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER FUNCTION; LIVER NODULE; MALE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DIET; DIETHYLNITROSAMINE; DRUG SYNERGISM; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; PHENOBARBITAL; PHOSPHATIDYLCHOLINES; RATS; RATS, SPRAGUE-DAWLEY; VITAMIN K 2;

EID: 34249314048     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.01.030     Document Type: Article

References (37)

1. Li Z.Q., He F.Y., Stehle C.J., Wang Z., Kar S., Finn F.M., et al. Vitamin K uptake in hepatocytes and hepatoma cells. Life Sciences 70 (2002) 2085-2100
2. Wang Z., Wang M., Finn F., and Carr B.I. The growth inhibitory effects of vitamin K and their actions on gene expression. Hepatology 22 (1995) 876-882
3. Otsuka M., Kato N., Shao R.X., Hoshida Y., Ijichi H., Koike Y., et al. Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. Hepatology 40 (2004) 243-251
4. Hitomi M., Yokoyama F., Kita Y., Nonomura T., Masaki T., Yoshiji H., et al. Antitumor effects of vitamins K1, K2 and K3 on hepatocellular carcinoma in vitro and in vivo. Int J Oncol 26 (2005) 713-720
5. Kuriyama S., Hitomi M., Yoshiji H., Nonomura T., Tsujimoto T., Mitoro A., et al. Vitamins K2, K3 and K5 exert in vivo antitumor effects on hepatocellular carcinoma by regulating the expression of G1 phase-related cell cycle molecules. Int J Oncol 27 (2005) 505-511
6. Koike Y., Shiratori Y., Sato S., Obi S., Teratani T., Imamura M., et al. Des-γ-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma. Cancer 91 (2001) 561-569
7. Yoshiji H., Kuriyama S., Noguchi R., Yoshii J., Ikenaka Y., Yanase K., et al. Amelioration of carcinogenesis and tumor growth in the rat liver by combination of vitamin K2 and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. Oncol Rep 15 (2006) 155-159
8. Yoshiji H., Kuriyama S., Noguchi R., Yoshii J., Ikenaka Y., Yanase K., et al. Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression. J Hepatol 42 (2005) 687-693
9. Mizuta T., Ozaki I., Eguchi Y., Yasutake T., Kawazoe S., Fujimoto K., et al. The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study. Cancer 15 (2006) 867-872
10. Munder P.G., Fischer H., Weltzien H.U., Oettgen H.F., and Westphal O. Lysolecithin analogs: a new class of immunopotentiators with antitumor activity. Clin Bull (Memorial Sloan-Kettering Cancer Center) 6 (1976) 80
11. Wright M.M., Howe A.G., and Zaremberg V. Cell membrane and apoptosis: role of cardiolipin, phosphatidylcholine, and anticancer lipid analogues. Biochem Cell Biol 82 (2004) 18-26
12. Yokoyama S., Sells M.A., Reddy T.V., and Lombardi B. Hepatocarcinogenic and promoting action of a choline-devoid diet in the rat. Cancer Res 45 (1985) 2834-2842
13. Newberne P.M. Lipotropic factors and oncogenesis. Adv Exp Med Biol 206 (1986) 223-251
14. Shinozuka H., Lombardi B., Sell S., and Iammarino R.M. Early histological and functional alterations of ethionine liver carcinogenesis in rats fed a choline-deficient diet. Cancer Res 38 (1978) 1092-1098
15. Yoshida L.S., Miyazawa T., Fujimoto K., and Kaneda T. Liver phosphatidylcholine hydroperoxidation provoked by ethionine-containing choline-deficient diet in mice. Lipids 25 (1990) 565-569
16. Shinozuka H., Lombardi B., Sell S., and Iammarino R.M. Enhancement of dl-ethionine-induced liver carcinogenesis in rats fed a choline-devoid diet. J Natl Cancer Inst 61 (1978) 813-817
17. 2) levels in the initiation and promotion of hepatocellular carcinogenesis in old rats. Exp Gerontol 36 (2001) 255-265
18. Sirica A.E., Wilkerson C.S., Wu L.L., Fitzgerald R., Blanke R.V., and Guzelian P.S. Evaluation of chlordecone in a two-stage model of hepatocarcinogenesis: a significant sex difference in the hepatocellular carcinoma incidence. Carcinogenesis 10 (1989) 1047-1054
19. Anupam B., Alok S., and Malay C. Further evidence for chemopreventive potential of β-carotene against experimental carcinogenesis: diethylnitrosamine-initiated and phenobarbital-promoted hepatocarcinogenesis is prevented more effectively by β-carotene than by retinoic acid. Nutr Cancer 37 (2000) 89-98
20. 3 inhibits rat liver ultrastructural changes in diethylnitrosamine-initiated and phenobarbital promoted rat hepatocarcinogenesis. J Cell Biochem 81 (2001) 357-367
21. Lii C.K., Ou C.C., Liu K.L., Liu J.Y., Lin W.L., and Chen H.W. Suppression of altered hepatic foci development by a high fish oil diet compared with a high corn oil diet in rats. Nutr Cancer 38 (2000) 50-59
22. Schulte-Hermann R., Timmermann-Trosiener I., and Schuppler J. Facilitated expression of adaptive responses to phenobarbital in putative pre-stages of liver cancer. Carcinogenesis 7 (1986) 1651-1655
23. Vijayaraghavan M., Wanibuchi H., Takada N., Yano Y., Otani S., Yamamoto S., et al. Inhibitory effects of S-methylcysteine and cysteine on the promoting potential of sodium phenobarbital on rat liver. Carcinogenesis Jpn J Cancer Res 91 (2000) 780-785
24. 3 inhibits placental glutathione S-transferase positive foci in rat liver carcinogenesis. Life Sci 68 (2000) 217-231
25. Bishayee A., and Chatterjee M. Inhibitory effect of vanadium on rat liver carcinogenesis initiated with diethylnitrosamine and promoted by phenobarbital. Br J Cancer 71 (1995) 1214-1220
26. Winokur T.S., and Lieberman M.W. Immunofluorescent analysis of γ-glutamyl transpeptidase and glutathione-S-transferase-P during the initial phase of experimental hepatocarcinogenesis. Carcinogenesis 11 (1990) 365-369
27. Reynolds E.S., and Moslen M.T. In vivo covalent binding of 14CCl4 metabolites in liver microsomal lipids. Biochem Biophys Res Commun 57 (1974) 747-750
28. Aleynik S.I., Leo M.A., Takeshige U., Aleynik M.K., and Lieber C.S. Dilinoleoylphosphatidylcholine is the active antioxidant of polyenylphosphatidylcholine. J Invest Med 47 (1999) 507-512
29. Steel G.G., and Peckham M.J. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5 (1979) 85-91
30. Kano Y., Suzuki K., Akutsu M., Suda K., Inoue Y., Yoshida M., et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 50 (1992) 604-610
31. Dalenc F., Giamarchi C., Petit M., Poirot M., Favre G., and Faye J.C. Farnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways. Breast Cancer Res 76 (2005) 1159-1167
32. Campbell H.A., Pitot H.C., Potter V.R., and Laishes B.A. Application of quantitative stereology to the evaluation of enzyme-altered foci in rat liver. Cancer Res 42 (1982) 465-472
33. Maxuitenko Y.Y., MacMillan D.L., Kensler T.W., and Roebuck B.D. Evaluation of the post-initiation effects of oltipraz on aflatoxin B1-induced preneoplastic foci in a rat model of hepatic tumorigenesis. Carcinogenesis 14 (1993) 2423-2425
34. Pitot H.C., Campbell H.A., and Maronpot R. Critical parameters in the quantitation of the stages, promotion and progression in one model of hepatocarcinogenesis in the rat. Toxicol Pathol 17 (1989) 594-605
35. Nakao A., Suzuki Y., Isshiki K., Kimura Y., Takeda S., Kishimoto W., et al. Clinical evaluation of plasma abnormal prothrombin (DES-γ-carboxy prothrombin) in hepatobiliary malignancies and other diseases. Am J Gastroenterol 86 (1991) 62-66
36. Nakao A., Virji A., Iwaki Y., Carr B., Iwatsuki S., and Starzl E. Abnormal prothrombin (DES-γ-carboxy prothrombin) in hepatocellular carcinoma. Hepatogastroenterology 38 (1991) 450-453
37. Inoue S., Nakao A., Harada A., Nonami T., and Takagi H. Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma. Am J Gastroenterol 89 (1994) 2222-2226